These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31508900)

  • 1. Changes in conditional net survival and dynamic prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy.
    Narita S; Nomura K; Hatakeyama S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Mitsuzuka K; Tochigi T; Tsuchiya N; Ohyama C; Arai Y; Nagashima K; Habuchi T
    Cancer Med; 2019 Nov; 8(15):6566-6577. PubMed ID: 31508900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes and prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy: a retrospective multicenter study in Japan.
    Narita S; Hatakeyama S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Koizumi A; Mitsuzuka K; Tochigi T; Tsuchiya N; Ohyama C; Arai Y; Nomura K; Habuchi T
    Int J Clin Oncol; 2020 May; 25(5):912-920. PubMed ID: 31919691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Outcomes of Patients with High-risk Metastatic Hormone-naïve Prostate Cancer: A 3-year Interim Analysis of the Observational J-ROCK Study.
    Miyake H; Matsumoto R; Fujimoto K; Mizokami A; Uemura H; Kamoto T; Kawakami S; Nakamura K; Maekawa S; Shibayama K; Watanabe A; Ito M; Tajima Y; Matsuyama H; Uemura H
    Eur Urol Oncol; 2024 Jun; 7(3):625-632. PubMed ID: 38296736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The oncological outcome and validation of Japan Cancer of the Prostate Risk Assessment score among men treated with primary androgen-deprivation therapy.
    Shiota M; Yokomizo A; Takeuchi A; Imada K; Kiyoshima K; Inokuchi J; Tatsugami K; Naito S
    J Cancer Res Clin Oncol; 2015 Mar; 141(3):495-503. PubMed ID: 25227457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy.
    Kadono Y; Nohara T; Ueno S; Izumi K; Kitagawa Y; Konaka H; Mizokami A; Onozawa M; Hinotsu S; Akaza H; Namiki M
    World J Urol; 2016 Feb; 34(2):261-7. PubMed ID: 26047654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy.
    Wang Y; Xu F; Pan J; Zhu Y; Shao X; Sha J; Wang Z; Cai Y; Liu Q; Dong B; Xue W; Huang Y
    BMC Cancer; 2016 May; 16():329. PubMed ID: 27222030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Adamovich E; Lief J
    Int J Radiat Oncol Biol Phys; 2007 May; 68(1):34-40. PubMed ID: 17289288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes and prognostic factors in intermediate-risk prostate cancer: multi-institutional analysis of the Spanish RECAP database.
    Hervás A; Pastor J; González C; Jové J; Gómez A; Casaña M; Villafranca E; Mengual JL; Muñoz V; Henriquez I; Muñoz J; Collado E; Clemente J
    Clin Transl Oncol; 2019 Jul; 21(7):900-909. PubMed ID: 30536208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment plasma fibrinogen as an independent prognostic indicator of prostate cancer patients treated with androgen deprivation therapy.
    Wang Y; Yin W; Wang Z; Huang J; Pan J; Zhu Y; Xu F; Shao X; Sha J; Cai Y; Liu Q; Dong B; Xue W; Huang Y
    Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):209-15. PubMed ID: 26951714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of statins in combination with androgen deprivation therapyin patients with advanced prostate cancer: A large observational study.
    Anderson-Carter I; Posielski N; Liou JI; Khemees TA; Downs TM; Abel EJ; Jarrard DF; Richards KA
    Urol Oncol; 2019 Feb; 37(2):130-137. PubMed ID: 30528885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of time to prostate-specific antigen (PSA) nadir and its relationship to survival beyond time to PSA nadir for prostate cancer patients with bone metastases after primary androgen deprivation therapy.
    Teoh JY; Tsu JH; Yuen SK; Chan SY; Chiu PK; Lee WM; Wong KW; Ho KL; Hou SS; Ng CF; Yiu MK
    Ann Surg Oncol; 2015 Apr; 22(4):1385-91. PubMed ID: 25234025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.
    Touijer KA; Karnes RJ; Passoni N; Sjoberg DD; Assel M; Fossati N; Gandaglia G; Eastham JA; Scardino PT; Vickers A; Cozzarini C; Montorsi F; Briganti A
    Eur Urol; 2018 Jun; 73(6):890-896. PubMed ID: 29042125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer.
    Rusthoven CG; Jones BL; Flaig TW; Crawford ED; Koshy M; Sher DJ; Mahmood U; Chen RC; Chapin BF; Kavanagh BD; Pugh TJ
    J Clin Oncol; 2016 Aug; 34(24):2835-42. PubMed ID: 27325855
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Rezk M; Chandra A; Addis D; Møller H; Youssef M; Dasgupta P; Yamamoto H
    BMJ Open; 2019 Mar; 9(3):e025161. PubMed ID: 30852544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment elevated prognostic nutritional index predicts a favorable prognosis in patients with prostate cancer.
    Li B; Lu Z; Wang S; Hou J; Xia G; Li H; Yin B; Lu W
    BMC Cancer; 2020 Apr; 20(1):361. PubMed ID: 32349713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
    Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
    Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of early changes in serum biomarker levels in patients with newly diagnosed metastatic prostate cancer.
    Narita S; Nomura K; Hatakeyama S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Mitsuzuka K; Tochigi T; Tsuchiya N; Ohyama C; Arai Y; Nagashima K; Habuchi T
    Sci Rep; 2019 Aug; 9(1):12071. PubMed ID: 31427687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer-specific and net overall survival in older patients with de novo metastatic prostate cancer initially treated with androgen deprivation therapy.
    Narita S; Terada N; Nomura K; Sakamoto S; Hatakeyama S; Kato T; Matsui Y; Inokuchi J; Yokomizo A; Tabata KI; Shiota M; Kimura T; Kojima T; Inoue T; Mizowaki T; Sugimoto M; Kitamura H; Kamoto T; Nishiyama H; Habuchi T;
    Int J Urol; 2022 Oct; 29(10):1147-1154. PubMed ID: 35613936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
    Francini E; Gray KP; Xie W; Shaw GK; Valença L; Bernard B; Albiges L; Harshman LC; Kantoff PW; Taplin ME; Sweeney CJ
    Prostate; 2018 Sep; 78(12):889-895. PubMed ID: 29707790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of early changes in serum biomarkers following androgen deprivation therapy on clinical outcomes in metastatic hormone-sensitive prostate cancer.
    Sato H; Narita S; Tsuchiya N; Koizumi A; Nara T; Kanda S; Numakura K; Tsuruta H; Maeno A; Saito M; Inoue T; Satoh S; Nomura K; Habuchi T
    BMC Urol; 2018 May; 18(1):32. PubMed ID: 29739368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.